Real Hope For Cancer Patients | Precision Biologics

UNIQUE DISCOVERY PLATFORM

realize our potential

LEARN MORE

We have a platform of patient tumor
derived anticancer vaccines.

THERAPEUTICS

leaders in biotherapeutics

LEARN MORE

Our unique platform, combined with breakthroughs in biotechnology, enable us to produce targeted antibodies that weren’t possible just a few years ago.

COMPANION DIAGNOSTICS

explore our program

LEARN MORE

Our monoclonal antibodies are designed to target the tumor without harming healthy cells.

Precision Biologics is dedicated to improving the lives of cancer patients through its innovative therapeutic and diagnostic products.

Precision Biologics announces publication of a new review article in Expert Review of Vaccines, September 1st, 2024.

DATE: September 1, 2024

Precision Biologics Awarded New Patent on NEO-201 for Treg Depletion

DATE: July 22, 2024

Precision Biologics to present at the American Society for Clinical Oncology (ASCO) 2024 Annual Meeting

DATE: May 31, 2024

PRECISION BIOLOGICS TO PRESENT AT 7th INTERNATIONAL NEOANTIGEN SUMMIT, AMSTERDAM, NETHERLANDS, APRIL 29 - May 1, 2024

DATE: April 29, 2024

PRECISION BIOLOGICS TO PRESENT AT IMMUNO 2024, LONDON, UK, APRIL 25 - 26, 2024

DATE: April 25, 2024

American Association for Cancer Research (AACR) 2024 Annual Meeting, April 8, 2024, San Diego, CA, San Diego Convention Center

DATE: April 5, 2024

# of people living with cancer in the US

annual # of new cases of cancer in the US

annual # of deaths from cancer in the US

Discover our innovative Leaders.

Meet our Team

Officer, Board Member

Philip Arlen

President and CEO

Officer

Al Tsang

Chief Scientific Officer

Officer

Sharon A. Mavroukakis

RN, MS

Officer

Massimo Fantini

Director R & D

News and Events

Precision Biologics announces publication of a new review article in Expert Review of Vaccines, September 1st, 2024.

Precision Biologics announces that a review, entitled "Generation of the therapeutic monoclonal antibody NEO-201, derived...

Dr. Philip M. Arlen to Chair and Present at Cambridge Healthtech Institute Immuno-Oncology Summit 2024, August 7-9, 2024, Philadelphia, PA

Precision Biologics’ CEO, Dr. Philip M. Arlen, to Chair Therapeutic Cancer Vaccine Program, and lead...

Genetic Engineering and Biotechnology News (GEN) news article highlights Precision Biologics, Inc., August 1, 2024 Issue

Genetic Engineering and Biotechnology News (GEN) news article highlights Precision Biologics, Inc., August 1, 2024...

Home